Organon & Co. (OGN) Stock
Key stats
- Market cap
- $3.65B
- Price / Earnings ratio
- 17.1x
- EPS (TTM)
- $0.80
- Volume
- Loading
- 52-week high
- $13.89
- 52-week low
- $5.69
- Dividend yield
- 0.72%
- Dividend amount (latest)
- $0.02
- EPS vs analyst estimate
- +9.8%Q3 FY25 · $1.01 vs $0.92
Source: third-party data provider, as of November 13, 2026
EPS estimate: analyst consensus
Compare with OGN
Recent news

Organon (OGN) Q3 Earnings and Revenues Top Estimates
Organon (OGN) Q3 Earnings and Revenues Top Estimates
OGN

Organon Announces Quarterly Dividend
Organon Announces Quarterly Dividend
OGN

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
OGN

Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
OGN
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 64.68
- MACD 12/26/9
- 0.04
- EMA 9 of MACD
- 0.03
- MACD histogram
- 0.01
- SMA 50
- $13.75
- Price above SMA 50
- EMA 50
- $13.73
- Price above EMA 50
- SMA 200
- $11.70
- Price above SMA 200
- EMA 200
- $11.60
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market has no earnings per share expectations for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Organon (OGN) Q3 Earnings and Revenues Top Estimates
Organon (OGN) Q3 Earnings and Revenues Top Estimates
OGN

Organon Announces Quarterly Dividend
Organon Announces Quarterly Dividend
OGN

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
OGN

Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
OGN

Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting
Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting
OGN

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
OGN

Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
OGN

Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference
Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference
OGN

Is Trending Stock Organon & Co. (OGN) a Buy Now?
Is Trending Stock Organon & Co. (OGN) a Buy Now?
OGN

Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device
OGN
News tone: automated (AI) classification of the article's content, not a price prediction.
About Organon & Co.
Organon & Co. is a global pharmaceutical company focused on advancing women's health and well-being. Spun off from Merck & Co., Inc. in 2021, Organon is dedicated to addressing unmet medical needs in areas such as contraception, fertility, menopause, and gynecological disorders. With a portfolio of products and research initiatives aimed at improving the lives of women at various stages of their lives, Organon is committed to advancing healthcare solutions that empower women and promote their overall health. The company's mission is to make a meaningful difference in women's lives through innovative medical advancements and a dedication to women's healthcare excellence worldwide.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Joseph T. Morrissey Jr. | Chief Executive Officer | 1965 |
| Ms. Carrie Smith Cox | Executive Chair of the Board | 1959 |
| Mr. Matthew M. Walsh C.F.A. | Executive VP & CFO | 1967 |
| Ms. Rachel A. Stahler | Executive VP, Chief Information Officer and Chief Digital & Growth Officer | 1976 |
| Mr. Kirke Weaver | Executive VP, General Counsel & Corporate Secretary | 1973 |
| Ms. Jennifer Halchak | Head of Investor Relations | — |
| Mr. Daniel Karp | Chief Strategy Officer & Head of Corporate Development | 1978 |
| Mr. Aaron Falcione | Executive VP & Chief Human Resources Officer | 1971 |
| Mr. Vittorio Nisita | Executive VP and Head of Enterprise Services & Solutions | 1968 |
| Ms. Juliana Papa Drinane | Head of Manufacturing & Supply | — |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 64.68
- MACD 12/26/9
- 0.04
- EMA 9 of MACD
- 0.03
- MACD histogram
- 0.01
- SMA 50
- $13.75
- Price above SMA 50
- EMA 50
- $13.73
- Price above EMA 50
- SMA 200
- $11.70
- Price above SMA 200
- EMA 200
- $11.60
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -12.4 | +6.0 | ||||||||||
| 2022 | +2.4 | +13.2 | -6.8 | -8.0 | +18.3 | -10.6 | -7.4 | -10.4 | -18.8 | +8.8 | -1.4 | +5.7 |
| 2023 | +7.3 | -19.2 | -3.2 | +4.7 | -20.9 | +7.0 | +6.9 | +1.1 | -21.6 | -11.4 | -22.7 | +25.4 |
| 2024 | +13.2 | +1.0 | +7.1 | +0.6 | +13.3 | -3.2 | +7.6 | +3.2 | -13.4 | -0.3 | -12.2 | -4.2 |
| 2025 | +4.0 | +0.0 | +3.8 | -8.5 | -2.4 | +4.6 | -3.5 | -3.4 | +13.4 | -38.6 | +14.9 | -5.7 |
| 2026 | +18.0 | -11.1 | -16.7 | +115.8 | +0.4 | +1.3 | +0.1 | +1.5 | -0.4 | +0.9 | +0.5 |



